Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 3/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20202185 | 1.00 | ALDH1A1 (0.45) | ALDH1A1L3MBTL1NPSR1MAPTTSHR | |
| SCHEMBL20202184 | 1.00 | ALDH1A1 (0.45) | ALDH1A1L3MBTL1NPSR1MAPTTSHR | |
| SCHEMBL29931962 | 0.83 | PDE8B (0.42) | ALDH1A1L3MBTL1NPSR1MAPTTSHR | |
| SCHEMBL20187323 | 0.83 | KMT2A (0.43) | ALDH1A1MAPTTSHRKMT2AMEN1 | |
| SCHEMBL28887425 | 0.83 | KMT2A (0.43) | ALDH1A1MAPTTSHRKMT2AMEN1 | |
| SCHEMBL20187314 | 0.83 | KMT2A (0.43) | ALDH1A1MAPTTSHRKMT2AMEN1 | |
| SCHEMBL20187322 | 0.82 | ALDH1A1 (0.45) | ALDH1A1L3MBTL1NPSR1MAPTTSHR | |
| SCHEMBL28887434 | 0.81 | PIK3CD (0.39) | L3MBTL1NPSR1MAPTKMT2ALMNA | |
| SCHEMBL20187343 | 0.78 | ALDH1A1 (0.45) | ALDH1A1L3MBTL1NPSR1MAPTTSHR | |
| SCHEMBL20170496 | 0.76 | HSP90AA1 (0.56) | ALDH1A1L3MBTL1NPSR1MAPTTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3544972-B1 | HETEROARYLPHENOXY BENZAMIDE KAPPA OPIOID LIGANDS | PFIZER (US) | 2023-04-26 | — | — | EP | disclosed |
| CN-110234638-B | Heteroaryl phenoxy benzamide KAPPA opioid ligands | 辉瑞大药厂 | 2022-10-21 | — | — | CN | disclosed |
| EP-3544972-A1 | HETEROARYLPHENOXY BENZAMIDE KAPPA OPIOID LIGANDS | Pfizer Inc (US) | 2019-10-02 | — | — | EP | disclosed |
| US-10316021-B2 | Heteroarylphenoxy benzamide kappa opioid ligands | PFIZER INC. (US) | 2019-06-11 | — | — | US | disclosed |
| US-10316021-B2 | Heteroarylphenoxy benzamide kappa opioid ligands | PFIZER INC. (US) | 2019-06-11 | — | — | US | disclosed |
| US-20180148432-A1 | HETEROARYLPHENOXY BENZAMIDE KAPPA OPIOID LIGANDS | PFIZER INC. (US) | 2018-05-31 | — | — | US | disclosed |
| US-20180148432-A1 | HETEROARYLPHENOXY BENZAMIDE KAPPA OPIOID LIGANDS | PFIZER INC. (US) | 2018-05-31 | — | — | US | disclosed |
| US-20180148432-A1 | HETEROARYLPHENOXY BENZAMIDE KAPPA OPIOID LIGANDS | PFIZER INC. (US) | 2018-05-31 | — | — | US | disclosed |
| WO-2018096510-A1 | HETEROARYLPHENOXY BENZAMIDE KAPPA OPIOID LIGANDS | PFIZER INC. (US) | 2018-05-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10316021-B2 | Heteroarylphenoxy benzamide kappa opioid ligands | OPRK1, OPRD1, OPRM1 | ALDH1A1 1595/4885L3MBTL1 1121/4885NPSR1 32/4885 |
| US-20180148432-A1 | HETEROARYLPHENOXY BENZAMIDE KAPPA OPIOID LIGANDS | OPRK1, OPRD1, OPRM1 | ALDH1A1 1595/4885L3MBTL1 1121/4885NPSR1 32/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.